IRIS
MARTINI, Giulia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.289
AS - Asia 2.307
NA - Nord America 2.289
SA - Sud America 301
AF - Africa 34
OC - Oceania 3
Totale 10.223
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 3.816
US - Stati Uniti d'America 2.241
SG - Singapore 799
IE - Irlanda 475
CN - Cina 433
HK - Hong Kong 413
IT - Italia 379
VN - Vietnam 287
BR - Brasile 263
DE - Germania 186
KR - Corea 131
GB - Regno Unito 108
IN - India 80
FR - Francia 73
UA - Ucraina 54
JP - Giappone 44
FI - Finlandia 35
SE - Svezia 30
CA - Canada 27
AT - Austria 26
GR - Grecia 25
PK - Pakistan 25
TR - Turchia 22
NL - Olanda 18
PL - Polonia 17
AR - Argentina 14
BD - Bangladesh 12
CZ - Repubblica Ceca 12
IQ - Iraq 12
MX - Messico 12
EC - Ecuador 11
ID - Indonesia 11
ZA - Sudafrica 10
ES - Italia 9
BE - Belgio 8
MA - Marocco 7
AZ - Azerbaigian 5
CH - Svizzera 5
UZ - Uzbekistan 5
CO - Colombia 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
KE - Kenya 4
KG - Kirghizistan 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
PH - Filippine 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
AL - Albania 2
CL - Cile 2
GI - Gibilterra 2
JO - Giordania 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LT - Lituania 2
MY - Malesia 2
PE - Perù 2
PY - Paraguay 2
SN - Senegal 2
TH - Thailandia 2
TW - Taiwan 2
VE - Venezuela 2
AM - Armenia 1
AO - Angola 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
EG - Egitto 1
GA - Gabon 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
IS - Islanda 1
LB - Libano 1
PT - Portogallo 1
RO - Romania 1
SA - Arabia Saudita 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TJ - Tagikistan 1
Totale 10.223
Salva come PNG Salva come JPEG
Città #
Moscow 1.382
Dublin 465
San Jose 420
Singapore 414
Hong Kong 402
Santa Clara 303
Chandler 220
Seoul 131
Ashburn 121
Ho Chi Minh City 94
Jacksonville 94
Naples 91
Beijing 77
New York 77
Hefei 73
Hanoi 69
Dallas 65
Munich 61
Los Angeles 58
Bremen 55
Princeton 54
Roxbury 54
Bengaluru 43
The Dalles 40
Ann Arbor 30
Cambridge 30
Caserta 25
Medford 24
Da Nang 22
São Paulo 21
Vienna 16
Haiphong 15
Warsaw 14
Council Bluffs 13
Nuremberg 13
Rome 13
Amsterdam 11
Boardman 11
Brno 11
Des Moines 11
Elora 11
Tokyo 11
Turku 11
Wilmington 11
Aversa 10
Brooklyn 10
Milan 10
Rio de Janeiro 10
Falkenstein 9
Frankfurt am Main 9
Napoli 9
Orem 9
San Francisco 9
Atlanta 8
Chennai 8
Helsinki 8
Hải Dương 8
Lappeenranta 8
Rawalpindi 8
Tianjin 8
Brussels 7
Hillsboro 7
Shanghai 7
Bologna 6
City of London 6
Columbus 6
Denver 6
Dong Ket 6
Ercolano 6
Jakarta 6
Jinan 6
Nanjing 6
San Mateo 6
Woodbridge 6
Bahawalpur 5
Baku 5
Battipaglia 5
Belo Horizonte 5
Campinas 5
Guangzhou 5
Guayaquil 5
Istanbul 5
London 5
Manchester 5
Mountain View 5
Mumbai 5
Ninh Bình 5
Anantapur 4
Baghdad 4
Bari 4
Bishkek 4
Biên Hòa 4
Boston 4
Giugliano in Campania 4
Guarulhos 4
Houston 4
Johannesburg 4
Madrid 4
Montreal 4
Piscataway 4
Totale 5.532
Salva come PNG Salva come JPEG
Nome #
Beyond N staging in colorectal cancer: Current approaches and future perspectives 218
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 201
AXL is an oncotarget in human colorectal cancer 194
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 182
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 177
Immunotherapy for head and neck cancer: Present and future 171
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 170
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 159
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 159
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 158
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 158
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 157
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 157
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 157
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 156
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 150
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 149
Clinical management of metastatic colorectal cancer in the era of precision medicine 149
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 148
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 146
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 146
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 145
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 144
Cancer cells adapt FAM134B/BiP mediated ER-phagy to survive hypoxic stress 144
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 144
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 142
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 139
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 139
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 139
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 138
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 137
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 137
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 134
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 133
Case report of unusual synchronous anal and rectal squamous cell carcinoma: clinical and therapeutic lesson 131
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 131
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial 129
Pimasertib hydrochloride 127
BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer 126
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 123
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 123
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 122
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study 121
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 121
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 120
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer 120
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 119
A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy 118
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? 117
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 116
Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives 116
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 115
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 115
How I treat anal squamous cell carcinoma 115
Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941 115
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation 114
Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives 114
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial 112
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 112
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 110
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data 109
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC 107
Feasibility of next-generation sequencing in clinical practice: Results of a pilot study in the Department of Precision Medicine at the University of Campania ' Luigi Vanvitelli' 107
Skin toxicity as predictor of survival in refractory patients with ras wild‐type metastatic colorectal cancer treated with cetuximab and avelumab (Cave) as rechallenge strategy 105
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case 102
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines 102
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression 101
Implication of the Hedgehog pathway in hepatocellular carcinoma. 101
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy 99
ROLE OF THE HEDGEHOG PATHWAY IN MEDIATING RESISTANCE TO ANTI-EGFR TYROSINE KINASE INHIBITORS IN NON SMALL CELL LUNG CANCER 98
“Aging and epigenetic implications in radiotherapy: The promise of BNCT” 95
Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer 94
Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer 92
Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer 89
The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer 88
Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update 88
Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. 85
Targeting the EGFR signalling pathway in metastatic colorectal cancer 84
RNF43- And NOTCH1-mutated chemotherapy and Anti-EGFR-refractory colorectal cancer: Should clonality guide target prioritization with investigational therapies? 81
Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments 79
Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer 75
Off-label drug use in oncology: integrating molecular and genetic analysis in an academic center's real-world approach 12
First-line immunotherapy combination in squamous cell anal carcinoma: hope in a neglected disease 11
Cardio-Oncology Challenges in Elderly Patients 9
BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives 9
Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy 8
Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial 8
Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM study 7
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial 7
Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial 5
Totale 10.436
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.770
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.770
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202161 0 0 0 0 0 0 0 0 0 22 28 11
2021/2022399 8 12 7 7 78 9 33 7 20 48 48 122
2022/2023939 99 17 25 71 125 78 4 41 426 8 26 19
2023/2024473 49 22 13 19 135 74 17 16 8 9 36 75
2024/20251.603 42 39 30 63 215 219 174 186 208 175 135 117
2025/20266.514 297 316 307 258 566 3.532 383 390 312 153 0 0
Totale 10.436